Relapse-Free and Overall Survival in Patients With Pathologic Stage II Nonseminomatous Germ Cell Cancer Treated With Etoposide and Cisplatin Adjuvant Chemotherapy
- 1 February 2004
- journal article
- clinical trial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (3) , 464-467
Abstract
Purpose: To assess the long-term relapse-free survival and overall survival of patients with stage II nonseminomatous germ cell tumor (NSGCT) who received two cycles of adjuvant etoposide and cisplatin (EP) after primary retroperitoneal lymph node dissection. Patients and Methods: Eighty-seven patients with completely resected pathologic stage II NSGCT were treated with adjuvant EP chemotherapy. Adjuvant EP consisted of two cycles of etoposide (100 mg/m2) plus cisplatin (20 mg/m2) per day, administered days 1 to 5 at a 21-day interval. Results: Ten patients (11%) had pN1 disease, 73 (84%) had pN2 disease, and four (5%) had pN3 disease. Eighty-six patients received two cycles of EP, and one patient received an additional two cycles of EP after a transient marker increase after his first cycle. Eighty-seven patients are alive, and 86 patients (99%) remain relapse-free at a median follow-up of 8 years (range, 0.9 to 13.5 years). Conclusion: Two cycles of adjuvant EP is highly effective in preventing relapse in patients with pathologic stage II pN1 and pN2 NSGCT. An alternative treatment strategy is surveillance with full-course chemotherapy at relapse. Because there is a higher risk of relapse for patients with pN2 disease, these patients are offered adjuvant chemotherapy.Keywords
This publication has 13 references indexed in Scilit:
- Paclitaxel, Ifosfamide, and Cisplatin Second-Line Therapy for Patients With Relapsed Testicular Germ Cell CancerJournal of Clinical Oncology, 2000
- Adjuvant bleomycin, etoposide and cisplatin in pathological stage II non-seminomatous testicular cancerEuropean Journal of Cancer, 2000
- Testicular Germ-Cell CancerNew England Journal of Medicine, 1997
- Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin.Journal of Clinical Oncology, 1997
- Etoposide and cisplatin adjuvant therapy for patients with pathologic stage II germ cell tumors.Journal of Clinical Oncology, 1995
- Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or EtoposideNew England Journal of Medicine, 1987
- Surgical Treatment of Patients with Stages I and II Nonseminomatous Testicular CancerJournal of Urology, 1985
- No Adjuvant Chemotherapy in Selected Patients with Pathologic Stage II Nonseminomatous Germ Cell Tumors of the TestisJournal of Urology, 1984
- Adjuvant Vinblastine, Actinomycin D, Bleomycin, Cyclophosphamide and Cis-Platinum Chemotherapy Regimen with and without Maintenance in Patients with Resected stage IIB Testis CancerJournal of Urology, 1982
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958